Christopher G Janson, M.D.
Dr. Christopher Janson is a NIH-funded physician-scientist with diverse training in neurology and the clinical neurosciences. He currently directs the human gene therapy center at Wright State Neuroscience Institute. His research laboratory focuses on vascular factors in neurodegeneration, including the role of the physiological brain barriers. Dr. Janson completed his undergraduate training in Biological Sciences at Stanford University and medical school at Yale University, followed by a postdoctoral fellowship in Gene Therapy at Thomas Jefferson University. He received additional clinical research training at UMDNJ-Robert Wood Johnson Medical School, where he was recipient of the NORD Roscoe Brady Fellowship and a principal co-investigator on the first NIH sponsored human gene therapy for a neurodegenerative disease. Dr. Janson completed his residency training in the clinical neurosciences at the University of Minnesota. He is board certified in Neurology by the American Board of Psychiatry & Neurology.
B.S. - Stanford University
M.D. - Yale University School of Medicine
My lab's focus is vascular contributions to dementia, in particular the role of meninges and other CSF-blood barrier tissues in Alzheimer's disease. We use in vitro and in vivo approaches to model the physiological brain barriers. Our mission is to achieve a better understanding of the physiology of aging, and ultimately to advance novel treatment approaches for Alzheimer's disease. My laboratory also has pioneered clinical gene therapy for ultra-rare diseases. We are currently the world's leading site for targeted gene therapy of Canavan disease, in collaboration with Dayton Children's Hospital.
American Academy of Neurology
Congress of Neurological Surgeons
North American Vascular Biology Organization
American Society for Cell & Gene Therapy (ASCGT)